258 results about "Cannabis substance" patented technology

The present invention relates to the use of cannabidiol (CBD) in the treatment of epilepsy which results from mutation of the KCNT1 gene. The CBD used is in the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) is present in an amount of from 0.02 to 0.1% (w / w). In an alternative embodiment the CBD may be in a synthetic form. In use the CBD may also be used concomitantly with one or more other anti-epileptic drugs (AED). The CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

A cartridge handling machine for vape type cartridges is provided, which may comprise a filling module for filling of cartridge bodies with viscous consumable fluids, particularly oils extracted from hemp and cannabis and compositions thereof. The cartridge handling machine may also comprise a capping module to provide for synchronized filling of the filled cartridges and capping the cartridges with a cap, such as a mouthpiece or other cap device developed for such cartridges. The individual filling and capping modules can be operated independent of each other such that the cartridge handling machine preferably comprises both a filling module and capping module that preferably are integrated together for synchronized operation, although these modules may also be constructed and operated as separate machines for the respective filling and capping of these types of vape cartridges.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

A disposable consumable with tobacco, hemp and / or cannabis therein is heated in a keyed receivor allowing conduction and convection. The consumable when inserted into a heating chamber via a keyed receivor will have one or more linear sections running axially that are in direct contact with the inner wall of the heating chamber and one or more linear sections that are remote from the inner wall with a volume of air between the cartridge and inner wall. Direct contact sections are heated via conduction through the heating chamber wall and the heated air volume forms a convection airflow for inhalation.

The system and techniques disclosed herein perform advanced and automatic age verification. The age verification system (AVS) is designed for automated and accurate age-restricted access control and age verification for the sale of age-controlled products. For example, the AVS can be employed to perform age-verification to permit the legal sale / purchase of age-controlled products such as alcohol, tobacco, cannabis, and the like, and Also, the AVS can be used to control legal access to age-restricted areas such as casinos, movie theaters, bars, and the like. The AVS can include a scanner for scanning a barcode printed on an identification (ID) card, an application, and a computer unit having output devices for generating visual, audible, and electronic signals to view, alert, and control age-restricted entry and control the sale of age-controlled products. The AVS can include automatic door lock functionality that supports age-restricted access control.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

A universal security implement for cannabis containers includes a security mechanism interface, a rim, and an immobilization implement. A user of the universal security implement for cannabis containers can fully secure a container by situating the universal security implement onto or into the container such that the immobilization implement fully precludes movement relative to the container. Moreover, the universal security implement's user may manipulate a security mechanism, such as a child-resistant cap, such that the security mechanism and the security mechanism interface interact to fully close and secure the contents within the container.

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Vaporizer pods for use with a vaporizer configured to generate vapor from dry herbs, and the vaporizer pods comprising reconstituted tobacco and very low THC reconstituted cannabis.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C1 (CBD-C1), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the 5 cannabinoid can be produced by synthetic means and a method for the production of CBD-C1 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C1 in models of disease.

A method and system for dispensing metered shots of cannabis-containing or hemp-containing concentrate into a receiving vessel. The method comprises the steps of (a) providing a control module that includes a touch screen; (b) communicating the control module with an endless piston pump or progressive cavity pump; (c) deploying a disposable plastic tube and plunger to dispense bulk concentrate into the pump; (d) positioning an empty receiving vessel into a position in relation to the dispenser using a conveyor, or a turntable, or by manually placing the receiving vessel into position; (e) dispensing a metered shot of the concentrate into the empty receiving vessel to prepare a filled vessel; and (f) re-positioning the filled vessel in registration with the conveyor or turntable so that the dispenser becomes engaged with a subsequent empty receiving vessel.

The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Disclosed herein are new cannabis compositions. In one embodiment, these new cannabis compositions are beverages, such as tea. In one embodiment, these new cannabis compositions are dehydrated beverages, such as powders or crystalline forms, which can be mixed with other components, like tea, and added to water.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

A Cannabis processing system comprises a grinding apparatus and a cell disruption apparatus. The grinding apparatus is configured to grind wet Cannabis cuttings to from a ground, wet Cannabis material comprising wet Cannabis particles having an average particle size within a range of from about 1 mm to about 3 mm. The cell disruption apparatus is downstream of the grinding apparatus and is configured to disrupt cell walls of plant cells of the wet Cannabis particles through one or more of flash freezing, a cellulose solvent, applied negative pressure, and vacuum distillation to facilitate removal of one or more cannabinoids within the plant cells of the wet Cannabis particles. Methods of processing Cannabis are also described.

The present disclosure relates to a filter for a smoking device, such as, but not limited to, a water pipe, or a cigarette, such as, but not limited to, a cannabis cigarette. The filter includes a body that is positionable over a mouthpiece of the smoking device, to filter impurities from smoke drawn therethrough, and a base that secures the body over the mouthpiece such that smoke is drawn therethrough, prior to inhalation by a user. The body can include one of more filtration layers, such as a first layer formed from a material selected to filter carcinogens and other impurities from the smoke prior to inhalation, and a second layer formed from a material selected to minimize or prevent the transmission of bacteria, viruses, or other contagions from a user's mouth to the smoking device. Each of the filtration layers can also be formed from one or more materials.

The present invention pertains to composition of a cannabis flavored improvement modification to Agave Derivatives, Liquors, Spirits, Distilled Beverages with formulation concentrates of various strengths of content.The cannabis flavored improvement to agave liquors begins with the process of using the cannabis plant and any of its extracted oils. Extracting the cannabis hashish or cannabis concentrate from Cannabis plant is the process of isolating the active ingredients: cannabin, cannabindon, cannabinine, and cannabinol using vegetable oil as solvent.In the agave, the agave hearts are cooked for a three-day period in underground oven pits of hot. rocks. The hearts are then crushed and mashed with a stone wheel then left to ferment in large barrels, where a small amount of the desired cannabis concentration and water are added. From the fermented mash is a liquid collected and distilled on clay or copper pots.The object of the cannabis flavored improvement to the agave derivatives has the advantage that such consumption will bring a refreshing effect as well as a cooling effect with intense stimulation and enjoyable taste experience. The present invention represents a new composition, method of preparation and applications, above and beyond the prior art of any agave derivatives.

The present invention provides for a method for obtaining an oil extract of cannabis. The method includes: (a) contacting cannabis biomass and an edible oil; (b) pressing between a pair of plates to provide spent cannabis and an oil extract of cannabis; and (c) separating the spent cannabis biomass and the oil extract of cannabis.

The present disclosure concerns methods for reducing nicotine dependency, i.e. by reducing tobacco smoking and promoting tobacco smoking secession; and by reducing marijuana dependency, i.e. by reducing marijuana smoking and promoting marijuana smoking cessation. More particularly the present disclosure concerns formulations of cannabinoids for use in reducing nicotine and marijuana dependency and promoting tobacco and marijuana smoking secession.

A vaporizing device includes a main body with a chamber extending between first and second openings. A condensation cup at the bottom of the chamber collects moisture and unvaporized substances. A stem extends through the second opening, and a mouthpiece extends through the first opening. The mouthpiece is a tubular member with an open end and a plurality of outlet openings. Stoppers secure the mouthpiece and stem within the chamber. A magnetic tool may be provided for applying vaporizable substances. In use, a section of the stem is locally heated to vaporization temperature, a substance is applied to the heated section, and vapor is drawn through the mouthpiece. The condensation cup prevents residue from reaching the user, maintaining cleanliness and hygiene. The device supports tool-free disassembly and is suitable for tobacco, cannabis, herbal blends, and concentrates.

Aseptic product processing systems and methods may include a hopper for introducing the product into the system and one or more components through which the product flows as it is processed, an enclosure surrounding one or more of the components, a gassing assembly comprising a plurality of gassing elements to maintain a substantially constant flow of inert gas over the product as it travels through the system components, and a filtered gas recirculation system that recirculates air or filtered gas through the enclosure. Such systems may be particularly advantageous for use in the cannabis industry.

The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.

A method and apparatus for retaining and extinguishing a cannabis cigarette and ash. The device with a body with a hollow cavity defining a first volume configured to extinguish the cannabis cigarette. This first volume tapering from a base to an opposing opening configured so that ash from the extinguished cannabis cigarette travels unidirectionally through the body and into the second end cap. The first end cap removably attachable to the body and a second end cap removably attachable to the opposite end of the body.

Long-lasting biodegradable subcutaneous implant with prolonged release of pharmacologically active substance pre-concentrated in polymer for the treatment of epilepsy using from 10 to 1000 mg essential oil extracted from Cannabis sativa and / or Cannabis indica (full or broad spectrum), 10 to 500 mg natural or synthetic tetrahydrocannabidiol (THC) isolate, 10 to 500 mg natural or synthetic cannabidiol (CBD) isolate, proportional combination of broad spectrum essential oil and CBD isolate, proportional combination of full spectrum essential oil and natural or synthetic CBD isolate, or proportional combination of natural or synthetic THC isolate and CBD isolate in polymeric matrix for adjuvant treatment of epilepsy, chronic pain and anxiety.

Compositions including Δ-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

An infusion kit and a method for using said kit for infusing a base substance with an additive substance. The additive substance is deposited into a permeable container, which is itself inserted into a non-permeable container. The base substance is then added to the non-permeable container and the non-permeable container is heated to thereby infuse the base substance with the additive substance. In one embodiment, the additive substance is roasted in the permeable container before infusion begins. In some embodiments, a non-permeable casing encloses the permeable container during roasting. In a preferred embodiment, the non-permeable container is heated by immersion in a temperature-controlled liquid bath system, such as would be found in a sous-vide or similar system. However, many other heating systems may be used. The additive substance may be derived from a plant, including but not limited to cannabis.

A fluid dispenser for discharging a nicotine and / or cannabis-containing fluid as a replacement for tobacco products consumed by burning same, including a fluid store for storing the fluid before output, a mouthpiece for discharging the fluid, a connecting fluid channel and an outlet valve assembly, with which the fluid channel is opened and closed. The outlet valve assembly has an elastically deformable tube section forming part of the fluid channel, and an actuation surface is located on an outer side of the dispenser for actuating the outlet valve assembly. This actuation surface is coupled to a tube-shaping segment, with which the tube section is deformed from a state in which the fluid channel is closed into a state in which the fluid channel is open by applying force to the actuation surface, to thereby allow for the discharge of fluid.

Filters of conventional design consist of a small paper tube which is filled with activated carbon and is closed at both ends by cellulose fibres and / or ceramic caps. Filters consisting only of cellulose also exist. The filters are used to rotate them with cigarette paper to form a cigarette or a joint. In normal use, one of the filter ends can be singed or burned when the cigarette or the joint is smoked to the end. In addition, specifically in the case of cannabis, oils emerging as a result of heat can clog the cellulose, but in particular also the small air passages of ceramic caps. The invention is intended, by means of the thermal insulation, to prevent scorching and clogging of the filter elements. The filter elements consist of cellulose and carbon or consist of ceramic cap / carbon or only cellulose and are to be placed centrally in a small tube consisting of paper. The cavities between the filter elements and the end of the tube are to be filled with specially shaped inserts made of paper or ceramic. The extension of the filter on both sides by the small paper tube is intended to ensure thermal insulation and to prevent the embers from being in direct contact with the cellulose filter or with the ceramic cap. As a result of the enlarged area, the specially shaped inserts made of paper or ceramic are intended to prevent clogging by emerging oils. In addition, the inserts prevent tobacco or cannabis particles from being able to fall unhindered into the paper tube.